Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors

Fig. 3

Level and change of ctDNA concentration in patients with clinical outcome data. a Paired CCF comparison of the definitive (Def.) and proceeding (Pro.) ctDNA tests of individual cases. The p-values are calculated by the Wilcoxon singed-rank test. Additionally, the null hypothesis of no difference among the groups is tested by the Kruskal–Wallis test and it gives a p-value of 1.36e-6. b Boxplot of CCF of the definitive ctDNA test. The pairwise p-values are calculated by the Wilcoxon rank sum test. c Waterfall plot of fold change of CCF and the matched TMB from the initial WES. Bars, fold change of CCF (left axis). Filled circles, TMB as counts per Mb sequences monitored (right axis). Additionally, the null hypothesis of no difference among the groups is tested by the Kruskal–Wallis test and it gives a p-value of 5.64e-10. PD: progressive disease, 15 cases; SD: stable disease, 26 cases; OR: objective response, 14 cases

Back to article page